Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins
Anne Xia1, Joanne M Stempak, Jesse Grist
1Division of Infectious Diseases, Department of Medicine, University of British Columbia , Vancouver, BC , Canada.
Background And Aims:
The link between Mycobacterium avium subsp. paratuberculosis (MAP) and Crohn's disease (CD) is supported by several studies that have reported the detection and isolation of MAP from human tissues, but causation has not yet been proven. Preliminary studies have shown higher levels of antibodies in sera from CD patients against secreted protein from MAP within human macrophages when compared to healthy controls. The immunogenicity of this protein in CD patients under different treatment regimes was evaluated.
Materials And Methods:
Sera of 110 CD patients, 82 ulcerative colitis (UC), and 150 healthy controls were collected and the presence of antibodies against the mycobacterial protein tyrosine phosphatase PtpA was assayed using ELISA.
Results:
A statistically significant difference in the level of antibodies against PtpA was measured in untreated CD patients versus healthy controls, but variation in the antibody levels was observed when patients were subjected to different treatment regimens. UC patients showed no differences in the levels of antibodies against PtpA when compared to healthy controls.
Conclusions:
CD patients under different drug treatments show a clear difference in the levels of antibodies against a protein secreted by MAP, suggesting that if MAP is active in the progress of CD, some treatments can be detrimental to its survival.
Insights
Higher antibody levels against Mycobacterium avium subsp. paratuberculosis (MAP) protein PtpA were found in Crohn
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- The potential link between Mycobacterium avium subsp. paratuberculosis (MAP) and Crohn's disease (CD) is suggested by MAP detection in human tissues.
- Previous studies indicate elevated antibodies against MAP secreted proteins in CD patients' sera compared to healthy individuals.
- The immunogenicity of a specific MAP protein (PtpA) in CD patients undergoing various treatments requires evaluation.
Purpose of the Study:
- To investigate the association between antibodies against MAP's PtpA and Crohn's disease.
- To assess how different treatment regimens affect antibody levels against PtpA in CD patients.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure antibodies against MAP's PtpA.
- Sera from 110 CD patients, 82 ulcerative colitis (UC) patients, and 150 healthy controls were analyzed.
Main Results:
- Significantly higher antibody levels against PtpA were observed in untreated CD patients compared to healthy controls.
- Antibody levels against PtpA varied among CD patients on different treatment regimens.
- No significant difference in PtpA antibody levels was found between UC patients and healthy controls.
Conclusions:
- CD patients exhibit distinct antibody level patterns against MAP's PtpA protein, influenced by their drug treatments.
- These findings suggest that certain treatments may impact MAP's activity or survival in CD patients, if MAP is involved in disease progression.
More Related Videos
15:57Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Published on: July 11, 2015
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis